EICHORCondition: Non-Small Cell Lung Cancer · Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is a multicenter, open-label, dose-finding/efficacy-expanding Phase IB/II clinical trial to evaluate SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer. The study consists of two phases: Phase IB to explore the safety/tolerability of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer; Phase II: To explore the efficacy of SHR-A2102 in combination with adebelimab in combination with SHR-8068 in patients with locally advanced or metastatic non-small cell lung cancer.
This description comes directly from the study's public registry record.
Xin Xu · 0518-82342973 · xin.xu@hengrui.com
Yunfei Zhang · 0518-82342973 · yunfei.zhang.yz277@hengrui.com
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: 1. Subjects are able to give voluntary informed consent, understand the study and are willing to follow and complete all the test procedures. 2. Age 18\~70 years old. 3. Pathologically confirmed unresectable locally advanced/metastatic non-small cell lung cancer. 4. At least one measurable lesion per RECIST v1.1 criteria. 5. ECOG PS score: 0-1. Exclusion Criteria: 1. Active or symptomatic brain metastases. 2. Previous diagnosis of any other malignancy. 3. Clinically symptomatic moderate to severe ascites; Uncontrollable or moderate or above pleural effusion, pericardial effusion. 4. Received anti-tumor therapy 4 weeks prior to initiation of study treatment. 5. Uncontrolled tumor-related pain. 6. Subjects with severe cardiovascular and cerebrovascular diseases.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Shanghai Chest Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06589778